Holen Sie sich die Stockscreener-App
57.24
2.45%
1.37
Handel nachbörslich:
56.18
-1.06
-1.85%
Schlusskurs vom Vortag:
$55.87
Offen:
$55.16
24-Stunden-Volumen:
1.34M
Relative Volume:
0.48
Marktkapitalisierung:
$9.51B
Einnahmen:
$1.06B
Nettoeinkommen (Verlust:
$-326.58M
KGV:
-27.23
EPS:
-2.1022
Netto-Cashflow:
$-977.73M
1W Leistung:
+1.20%
1M Leistung:
+4.21%
6M Leistung:
-28.98%
1J Leistung:
+33.58%
1-Tages-Spanne:
$55.16
$57.24
1-Wochen-Bereich:
$54.91
$57.66
52-Wochen-Spanne:
$41.70
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
57.24 | 9.39B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-04-10 | Fortgesetzt | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Ionis Pharmaceuticals Trades at 10.9x Sales as Pipeline Optimism Clashes With Valuation Reality - finance.biggo.com
Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales - Yahoo Finance
Empowered Funds LLC Increases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - marketbeat.com
ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks - TradingView
Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain? - Yahoo Finance
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - Stocktwits
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Handelsbanken Fonder AB - marketbeat.com
(IONS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Assessing Growth Potential with a 57.94% Upside - DirectorsTalk Interviews
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Business Wire
3 Healthcare Stocks Retail Investors May Recheck After The July Jobs Shock - Sahm
Ionis Pharmaceuticals Inc. R (ISI.DU) Q1 FY2026 earnings call transcript - finance.yahoo.com
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Dimensional Fund Advisors LP - marketbeat.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc.IONS - PR Newswire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock forecasts - Yahoo Finance UK
Michael Hayden Bought 34% More Shares In Ionis Pharmaceuticals - simplywall.st
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 72% Potential Upside Amidst Challenging Metrics - DirectorsTalk Interviews
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock - marketbeat.com
Perceptive Advisors LLC Makes New $37.84 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - marketbeat.com
Ionis Pharmaceuticals, Inc. (IONS) Stock Forecasts - Yahoo Finance
Ionis Earnings: Early Signs of Commercial Momentum for Tryngolza as Key Catalysts Approach - Morningstar
Ionis Pharmaceuticals (NASDAQ:IONS) Lowered to "Sell" Rating by Wall Street Zen - marketbeat.com
IONS5835891 Bond Profile — Key Metrics - TradingView
Ionis Pharmaceuticals (NASDAQ:IONS) Director Michael Hayden Buys 5,000 Shares - marketbeat.com
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook - TradingView
Ionis Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Ionis Pharmaceuticals Inc (IONS) Q2 2026 Earnings Call Highlight - GuruFocus
Ionis Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ionis Pharmaceuticals: Q2 Earnings Snapshot - Barchart.com
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire - Yahoo Finance
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS - GlobeNewswire
Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewi - The National Law Review
Ionis earnings ahead: Tryngolza launch in focus amid rivalry By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceutica - The National Law Review
Ionis Pharmaceuticals Inc (IONS) Cash Flow - TradingKey
Ionis Pharmaceuticals (IONS) Stock Analysis: Uncovering a Potential 62% Upside in the Biotech Sector - DirectorsTalk Interviews
Entropy Technologies LP Makes New $2.04 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Inc. (IONS) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Bank of New York Mellon Corp Sells 239,269 Shares of Ionis Pharmaceuticals, Inc. $IONS - marketbeat.com
Ionis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:IONS - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – DUS:ISI - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Connect - ACCESS Newswire
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by KBC Group NV - marketbeat.com
Ionis Pharmaceuticals Inc (IONS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ionis Pharmaceuticals Inc (IONS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Ionis Pharmaceuticals Inc (IONS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):